Industry News

• Moderna announces publication of preclinical data for chikungunya antibody program  Moderna announced publication of preclinical data in Science Immunology, showing that mRNA encoding a human monoclonal antibody against the chikungunya virus delivered in a proprietary lipid nanoparticle can protect from infection by the virus in vivo.
  May 17, 2019  
• STRATA Skin Sciences receives notice of filing delinquency from NASDAQ  STRATA Skin Sciences received written notification from The NASDAQ Stock Market May 17, 2019, that the Company has not yet filed either of its Quarterly Report or its Annual Report for the year ended December 31, 2018 with the SEC and does not comply with the continued listing requirements.
  May 17, 2019  
• Integrated stepped alcohol treatment for people in HIV care improves both HIV and alcohol  New clinical research supported by the NIH shows that increasing the intensity of treatment for alcohol use disorder over time improves alcohol-related outcomes among people with HIV. This stepped approach to AUD treatment also improves HIV-related disease measures in this patient population.
  May 17, 2019  
• Precision Therapeutics gains extension for Nasdaq compliance  Precision Therapeutics announced that Nasdaq has determined that the Company is eligible for a 180-day grace period, or until November 11, 2019, to regain compliance with its Bid Price Rule.
  May 17, 2019  
• Probiotic may suppress fatal brain inflammation  The existence of certain microorganisms in your gut may bolster the immune system’s ability to fend off a herpes viral attack that can cause fatal brain inflammation, reports a new City of Hope-led study. The study was published in Nature Communications.
  May 17, 2019  
• World Fuel to supply Gevo’s sustainable jet fuel for first European demonstration  Gevo announced it is supplying its sustainable and renewable alcohol-to-jet fuel to World Fuel Services Corporation, for use in business jets at the first ever European Fueling the Future: SAJF demonstration held at TAG Farnborough Airport.
  May 17, 2019  
• Exact Sciences reports new data reinforcing performance of Cologuard®  New research from Exact Sciences and Mayo Clinic demonstrates the ability of Cologuard to both screen large patient populations and consistently help detect colorectal cancers and pre-cancers regardless of lesion location.
  May 17, 2019  
• Achillion reports positive interim data for ACH-4471 phase 2 combination trial  Achillion reported interim data from a Phase 2 paroxysmal nocturnal hemoglobinuria trial assessing the safety and effectiveness of its oral small molecule factor D inhibitor ACH-4471 in combination with intravenous eculizumab.
  May 17, 2019  
• ADMA Biologics announces pricing of public offering of common stock  ADMA Biologics announced pricing of its underwritten public offering of 11,250,000 shares of its common stock at a public offering price of $4.00 per share with gross proceeds of $45 million. ADMA granted underwriters a 30-day option to purchase up to 1,687,500 additional shares of common stock.
  May 17, 2019  
• Ligand licenses VER250840 to Cumulus Oncology  Ligand announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor. Ligand will receive an upfront license fee, and is eligible to receive over $76 million.
  May 17, 2019  

   (next 10 articles)